Search Results
Your search for The A matches 33769 pages
Showing 17651 - 17700Response to Ibrutinib in Symptomatic Untreated Waldenström’s Macroglobulinemia
In a study reported in the Journal of Clinical Oncology, Treon et al found that ibrutinib monotherapy was highly active in patients with previously untreated Waldenström’s macroglobulinemia, with better response in patients without CXCR4 mutation. Ibrutinib has been shown to be active in ...
Monthly High-Dose Vitamin D and Cancer Risk
In a study reported in JAMA Oncology, Scragg et al found that monthly high-dose vitamin D supplementation, without calcium, was not associated with a reduced risk of developing cancer. Study Details The current analysis is a post hoc analysis of the Vitamin D Assessment (ViDA) study, which...
‘Super-Resolution’ MRI May Help Plan Radiotherapy Treatment in Lung Cancer
Physicists from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust combined standard two-dimensional magnetic resonance imaging (MRI) images of the chests of healthy volunteers to create 'super-resolution' videos, showing the lungs expanding and contracting. The...
Dabrafenib/Trametinib Combination Receives CHMP Recommendation for the Adjuvant Treatment of BRAF V600 Mutation–Positive Melanoma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for the adjuvant treatment of adult patients with stage III melanoma...
KEYNOTE-048: Pembrolizumab Monotherapy in Head and Neck Squamous Cell Carcinoma
The phase III KEYNOTE-048 trial, which is investigating pembrolizumab (Keytruda) for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), met a primary endpoint of overall survival (OS) as monotherapy in patients whose tumors expressed programmed cell death ...
Use of Analgesics and Ovarian Cancer–Specific Survival
In a prospective cohort study reported in The Lancet Oncology, Merritt et al found evidence that recent use of aspirin or nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) after diagnosis appears to improve ovarian cancer–specific survival. Study Details The study involved...
No Benefit of Adding Abiraterone to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Increasing PSA
The PLATO trial failed to show benefit of adding abiraterone (Zytiga)/prednisone to ongoing enzalutamide (Xtandi) vs abiraterone/prednisone in men with metastatic castration-resistant prostate cancer exhibiting rising prostate-specific antigen (PSA) during enzalutamide treatment. Results of the...
Forum of International Respiratory Societies Issues Statement on World Lung Cancer Day
On World Lung Cancer Day (August 1), the members of the Forum of International Respiratory Societies (FIRS) commemorate, celebrate, and support those impacted by lung cancer. FIRS continues to support the grassroots efforts of the lung cancer community to raise awareness about lung cancer and its...
European Commission Approves Trastuzumab Biosimilar
The European Commission (EC) has approved Trazimera, a biosimilar to trastuzumab (Herceptin), for the treatment of human epidermal growth factor (HER2)–overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. This approval...
New Tool for Assessing Frailty May Aid in Predicting Survival in Newly Diagnosed Multiple Myeloma
A new frailty index may aid in predicting overall survival for patients newly diagnosed with multiple myeloma, according to a study published by Mian et al in JCO Clinical Cancer Informatics. This tool is important because frailty is a critical factor in treatment decision-making for ...
ALTA-1L Trial of Brigatinib vs Crizotinib in ALK-Positive Advanced NSCLC Meets Primary Endpoint
The global, randomized, phase III ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1st Line) trial met its primary endpoint at the first prespecified interim analysis, with brigatinib (Alunbrig) demonstrating a statistically significant improvement in progression-free...
Childbearing Potential in Women With Hodgkin Lymphoma
In a Swedish study reported in the Journal of Clinical Oncology, Weibull et al found that childbearing potential in young women treated for Hodgkin lymphoma in more recent years is similar to that in the general population. Study Details The study included 449 women aged 18 to 40 years identified ...
CPX-351 Liposome in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
In a pivotal phase III trial reported in the Journal of Clinical Oncology, Lancet et al found that cytarabine and daunorubicin liposome (CPX-351, Vyxeos) significantly improved overall survival vs standard cytarabine plus daunorubicin (7+3 regimen) in older patients with newly diagnosed secondary...
FDA Approves Lusutrombopag for Thrombocytopenia in Adults With Chronic Liver Disease
Today, the U.S. Food and Drug Administration (FDA) approved lusutrombopag (Mulpleta) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. L-PLUS 1 and L-PLUS 2 Approval was based on two randomized, double-blind, placebo-controlled...
SPOP-Mutant Prostate Cancer Subtype, High PSA, and Prognosis
Conventional wisdom suggests that a high level of the protein prostate-specific antigen (PSA) in men with prostate cancer means a poor prognosis. However, this may not always be the case in men with a particular subtype of prostate cancer, according to a new study from Weill Cornell Medicine and...
Study Examines Right-Sided vs Left-Sided Colon Cancer Survival Rates
Patients with colorectal cancer tumors on the right side may have poorer 5-year survival rates than those whose tumors are located on the left side. However, a new large-scale retrospective study is the first to demonstrate a potential improvement of these outcomes. Study results show that nearly...
Psychosocial Effects of Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer
In a prospective study reported in the Journal of Clinical Oncology, Parker et al found that among women with nonhereditary breast cancer electing contralateral prophylactic mastectomy (CPM), fear and worry over breast cancer may be dominant at the time of surgical decisions without sufficient...
Adding Cisplatin to First-Line Treatment of Elderly Patients With Advanced NSCLC
A joint analysis of parallel phase III trials reported in the Journal of Clinical Oncology by Gridelli et al found no overall survival benefit of adding cisplatin to first-line treatment of elderly patients with advanced non–small cell lung cancer (NSCLC) without an EGFR mutation. Study...
FDA Approves Iobenguane I-131 for Rare Adrenal Gland Tumors
On July 30, the U.S. Food and Drug Administration (FDA) approved iobenguane I-131 (Azedra) injection for adult and pediatric patients (12 years and older) with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic...
Indocyanine Green in Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma
High rates of regional lymph node involvement and metastases are not uncommon in Merkel cell carcinoma. National Comprehensive Cancer Network (NCCN) Guidelines recommend sentinel lymph node biopsy (SLNB) for staging purposes in this malignancy. In a study by Knanckstedt et al in ...
FDA Grants Fast Track Designation to Galinpepimut-S in Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to galinpepimut-S for the treatment of multiple myeloma. Galinpepimut-S is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms tumor 1 (WT1) protein, which is present in an array of tumor types....
Quality of Life With Niraparib Maintenance vs Placebo in Patients With Recurrent Ovarian Cancer
In a study reported in The Lancet Oncology, Oza et al found that quality of life (QOL) based on patient-reported outcomes (PROs) was not worsened with niraparib (Zejula) maintenance vs placebo in the phase III ENGOT-OV16/NOVA trial in women with recurrent ovarian cancer who were in response to...
Ado-Trastuzumab Emtansine in HER2-Mutant Lung Cancer
As reported by Li and colleagues in the Journal of Clinical Oncology, the HER2-targeted antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) showed activity in advanced HER2-mutant lung adenocarcinoma. Study Details The current report involves a cohort of patients with HER2-mutant lung...
Following a Healthy Diet and Avoiding Alcohol May Reduce Overall Cancer Risk
The World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) has estimated that in developed countries, about 35% of breast cancers and 45% of colorectal cancers could be prevented with a better adherence to nutritional recommendations. A large prospective study evaluating...
FDA Approves Magnetic Device System for Guiding Sentinel Lymph Node Biopsies in Patients With Breast Cancer
The U.S. Food and Drug Administration (FDA) recently approved a magnetic device system for guiding lymph node biopsies in patients with breast cancer undergoing mastectomy. The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to ...
Ability of Assay to Predict Response to Immunotherapy in Patients With Advanced Gastric Cancer
Researchers from Samsung Medical Center and Guardant Health, Inc have demonstrated the feasibility of determining a measure analogous to tumor mutation burden, a promising biomarker that may predict patient response to certain immunotherapies, utilizing the Guardant360 assay, a...
Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer
In a study reported in JAMA Oncology, Morrow and colleagues found that surgeon acceptance of more limited surgery in early breast cancer was more likely among high-volume surgeons and those preferring a surgical margin of “no ink on tumor.” As noted by the authors, the American College ...
Biomarker-Integrated Risk Model for Lung Cancer
As reported in JAMA Oncology by the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, incorporating biomarkers into a lung cancer risk prediction model may improve performance compared with risk based on age and smoking exposure alone....
New Study Calls for Continued Aggressive Treatment for Breast Cancer in Women Under 40
A new study from the Stanford Cancer Institute found that young women who are treated with chemotherapy for breast cancer but have residual tumor in either the breast or lymph nodes have higher chances of recurrence compared to those with no evidence of any residual invasive...
Robot-Assisted Laparoscopic Prostatectomy vs Open Radical Retropubic Prostatectomy in Newly Diagnosed Prostate Cancer
In an Australian phase III trial reported in The Lancet Oncology, Coughlin et al found similar functional outcomes at 2 years with robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy in men with newly diagnosed clinically localized prostate cancer. Study Details In ...
Complementary Therapy for Cancer and Refusal of Conventional Treatment
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from Yale Cancer Center and the Cancer Outcomes, Public Policy and Effectiveness...
IMpower 132: Atezolizumab in Combination With Pemetrexed and Platinum-Based Chemotherapy in Advanced Nonsquamous NSCLC
The phase III IMpower132 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of atezolizumab (Tecentriq) plus chemotherapy (cisplatin or carboplatin plus pemetrexed [Alimta]) reduced the risk of disease worsening or death compared to chemotherapy...
Quality-of-Life and Patient-Centered Outcomes With Olaparib Maintenance in Relapsed Ovarian Cancer
In the phase III SOLO2 trial reported in The Lancet Oncology, Friedlander et al found that olaparib maintenance therapy did not worsen health-related quality of life vs placebo in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1 or BRCA2 mutation. In the study, maintenance...
Alan S. Rabson, MD, Long-Time NCI Deputy Director and Cancer Research Stalwart, Dies at Age 92
MANY IN the cancer research and National Institutes of Health (NIH) community are mourning the loss of long-time National Cancer Institute (NCI) senior leader Alan S. Rabson, MD, who died on July 4 at the age of 92. With a distinguished scientific career that spanned 6 decades and included...
NIMHD Selects Recipients of the Minority Health and Health Disparities Research Innovation Award
THE NATIONAL INSTITUTE on Minority Health and Health Disparities (NIMHD), part of the National Institutes of Health (NIH), has selected recipients of the 2018 William G. Coleman, Jr, PhD, Minority Health and Health Disparities Research Innovation Award. Now in its second year, this competitive...
Pseudosophisticated Language and Needless Confusion?
I’ve been a loyal ASCO member since the early 1970s (aka “back in the day”) and wanted to share a growing pet peeve. I thought of attacking an individual author, but my sense tells me the source of my annoyance is really now a cultural problem and one that can only be fixed at the editor level....
Immunotherapy Gave Me Back My Life
Despite the fact that my father was a smoker and I watched him die a horrible death from lung cancer in the 1970s, until 4 years before my own lung cancer diagnosis in 2012, I, too, was a heavy smoker for most of my adult life. Still, cancer was the farthest thing from my mind when I made an...
Compassionate ASCO Print Resource for Families Facing Serious Illness
The ASCO Answers Advanced Cancer Care Planning booklet contains comprehensive information about how patients can communicate directly and honestly about advanced cancer and end-of-life care with their friends, family, and children, as well as the health-care team. With this expert resource,...
Long-Term Follow-up of Women With DES-Related Vaginal and Cervical Clear Cell Adenocarcinoma
In a letter to the editor of The New England Journal of Medicine, Dezheng Huo, MD, of the University of Chicago, Chicago, and colleagues described the long-term outcomes of women with vaginal and cervical clear cell adenocarcinoma associated with prenatal exposure to the synthetic nonsteroidal...
Risk of Breast Cancer After Negative Screening Mammography
A study reported in JAMA Oncology by Anne Marie McCarthy, PhD, of the Division of General Internal Medicine, Massachusetts General Hospital, and colleagues identified the risk of interval breast cancer after negative screening mammography, including the risk of poor-prognosis breast cancer. The...
Circulating Tumor Cells and Adjuvant Radiotherapy in Early Breast Cancer
In a study reported in JAMA Oncology by Chelain R. Goodman, MD, PhD, of the Department of Radiation Oncology at Northwestern University Feinberg School of Medicine, and colleagues, adjuvant radiotherapy was associated with better outcome in patients with early breast cancer who had detectable...
Multiple-Gene Sequencing vs BRCA1/2-Alone Testing After Breast Cancer Diagnosis
In a retrospective cohort study reported in JAMA Oncology by Allison W. Kurian, MD, of Stanford University School of Medicine, and colleagues found that use of germline multiple-gene sequencing has become more common than BRCA1/2-alone sequencing after breast cancer diagnosis in clinical practice. ...
Journal of Oncology Practice Launches New Blog to Facilitate Discussions on Care Delivery Topics
The Journal of Oncology Practice (JOP) launched a new care delivery blog, JOP DAiS(Discussion & Analysis in Short), to serve as a forum for commentary and analysis on issues affecting the mechanisms of oncology care delivery. This new platform will be a way to collaborate, debate, and discuss...
New International Journal Advances in Cell & Gene Therapy Now Available, Names Editors-in-Chief, Deputy Editors
A NEW INTERNATIONAL JOURNAL, Advances in Cell & Gene Therapy, recently published its inaugural issue in May 2018. The new publication aims to provide a forum for authors to share their newest results, views, and visions in the field of cell and gene therapy. The journal will be published on a...
Bevacizumab Plus Chemotherapy in Advanced Ovarian Cancer
ON JUNE 13, 2018, bevacizumab (Avastin) was granted approval for treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection1,2. The...
Be Prepared to Answer—and Ask—Questions About Integrative Therapy
ASCO HAS ENDORSED the recommendations in the Society for Integrative Oncology (SIO) clinical practice guidelines for integrative therapies during and after breast cancer.1,2 The guidelines “are clear, thorough, and based on the most relevant scientific evidence,” wrote the ASCO expert panel that...
Correction
The article “A Commitment to Innovation, Gender Equality, and Family Legacy Inspire Endowed Young Investigator Award Gifts for ASCO’s Conquer Cancer Foundation” in the May 25, 2018, issue included an incorrect quote attributed to Murdo Gordon. The corrected article is available online at...
ASCO Endorses Guidelines for Integrative Therapies During and After Breast Cancer Treatment
RECOMMENDATIONS IN the Society for Integrative Oncology (SIO) clinical practice guidelines for integrative therapies during and after breast cancer treatment “are clear, thorough, and based on the most relevant scientific evidence,” concluded an ASCO expert panel that reviewed the guidelines.1,2...
ASCO, Conquer Cancer Congratulate 2018 Grant and Award Recipients
ASCO’s Conquer Cancer Foundation presented more than $7.3 million in grants and awards to exceptional oncology researchers at the 2018 ASCO Annual Meeting. ASCO and Conquer Cancer congratulate the recipients and offer their profound thanks to those who generously supported these awards. Visit...
Sagar Lonial, MD, on Multiple Myeloma: Sequencing Therapies
Sagar Lonial, MD, of the Emory University School of Medicine, discusses the importance of planning for relapse based on the treatment a patient has received, new targets for refractory myeloma, and the role of cellular therapy.
